Newsroom

TORONTO--(BUSINESS WIRE)--The union representing frontline workers at the Workplace Safety and Insurance Board (WSIB) remains fully committed to reaching a fair deal and ending the ongoing strike. Union negotiators have been at the bargaining table every day this week, prepared and available to bargain in good faith. Despite our continued presence and dedication, the WSIB refused to meet to engage in discussion yesterday (Saturday) about the issues affecting the membership. The WSIB continues t...

WEST HOLLYWOOD, Kalif.--(BUSINESS WIRE)--Grindr, the Global Gayborhood in Your Pocket™ mit durchschnittlich mehr als 14,6 Mio monatlichen aktiven Nutzern, hat heute die globale Einführung von Right Now bekannt gegeben. Das ist die neueste, auf entsprechender Absicht beruhende Funktion, über die Menschen sofort miteinander in Kontakt treten können. Right Now ist ein Echtzeit-Feed, über den Nutzer von Grindr für eine Stunde Text und Fotos freischalten können, um Gleichgesinnten genau mitzuteilen,...

TAIPEI, Taïwan--(BUSINESS WIRE)--Il est fait référence à l’offre publique d’achat simplifiée (l’Offre) et à la procédure de retrait obligatoire mise en œuvre le 10 décembre 2024 par TCC Europe Holdings B.V. (anciennement dénommée Taiwan Cement Europe Holdings B.V.) (TCEH), une filiale indirecte de TCC Group Holdings Co., Ltd (TWSE : 1101), sur les actions de NHOA S.A. (NHOA), conformément à la décision de conformité de l’Autorité des marchés financiers en date du 5 novembre 2024 (Avis AMF n° 22...

TAIPEI, Taiwan--(BUSINESS WIRE)--Reference is made to the simplified tender offer (the Offer) and squeeze-out transaction completed on December 10, 2024, by TCC Europe Holdings B.V. (formerly known as Taiwan Cement Europe Holdings B.V.) (TCEH), an indirect subsidiary of TCC Group Holdings Co., Ltd (TWSE: 1101), on the shares of NHOA S.A. (NHOA), pursuant to the clearance decision (conformité) of the French Autorité des marchés financiers dated November 5, 2024 (AMF Notice no. 224C2193). Former...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today presented the first data for casdatifan plus cabozantinib in an oral presentation by Dr. Toni K. Choueiri, Dana-Farber Cancer Institute, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. “I was very encouraged to see that nearly half of patients had a...

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of Treace Medical Concepts, Inc. (NASDAQ: TMCI) between May 8, 2023 and May 7, 2024. Treace Medical describes itself as a “medical technology company focused on advancing the standard of care for the surgical management of bunion and related midfoot deformities.” For more information, submit a form, email attorney Phillip K...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Results from three trials continue to demonstrate the potential of DATROWAY® (datopotamab deruxtecan) in combination with various immunotherapies to improve outcomes in patients with non-small cell lung cancer (NSCLC) across multiple stages of the disease. These results from TROPION-Lung02, TROPION-Lung04 and NeoCOAST-2 were presented at the 2025 American Society of Clinical Oncology (#ASCO25) Annual Meeting. DATROWAY is a specifically engineered TR...

FRISCO, Texas--(BUSINESS WIRE)--Excelhire, the AI-powered hiring intelligence platform, proudly announces Balaji Karumanchi as its Founder and Chief Executive Officer....

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the expansion of Tempus One—its generative AI clinical assistant—with direct integration into electronic health record (EHR) systems. By integrating AI at every point of the clinical care process, the expanded capabilities of Tempus One offer physicians in oncology and beyond more support in treatment decisions. Tempus One is un...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival (EFS) versus chemotherapy alone. Patients were treated with neoadjuvant IMFINZI in combination with che...